Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Spratt

Showing results (321-330 of 498) with videos related to

Pageof 50
Sort By:
Nature Reviews. Urology|October 18, 2024
Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwardsEdward Christopher Dee, Rebecca Todd, Kenrick Ng, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2017
National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate CancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
The Prostate|June 3, 2022
Genomic biomarkers to guide precision radiotherapy in prostate cancerPhilip Sutera, Matthew P Deek, Kim Van der Eecken, et al.
Cancer|June 29, 2019
Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national databaseAmandeep R Mahal, Santino Butler, Idalid Franco, et al.
Nature Communications|November 19, 2025
Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironmentSebastian Krossa, Maria K Andersen, Elise M Sandholm, et al.
JNCI Cancer Spectrum|April 24, 2026
Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trialPatrick Lewicki, Arnav Srivastava, Ralph Jiang, et al.
European Urology|March 14, 2024
Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN StudySoumyajit Roy, Fred Saad, Shawn Malone, et al.
European Urology Focus|July 30, 2017
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
European Urology Open Science|January 15, 2026
Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific OutcomesRyan M Putney, Purvish Trivedi, Shivanshu Awasthi, et al.
European Urology|December 14, 2020
A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)Luca F Valle, Eric J Lehrer, Daniela Markovic, et al.
Pageof 50

Showing results (321-330 of 498) with videos related to

Sort By:
Pageof 50
Nature Reviews. Urology|October 18, 2024
Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwardsEdward Christopher Dee, Rebecca Todd, Kenrick Ng, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2017
National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate CancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
The Prostate|June 3, 2022
Genomic biomarkers to guide precision radiotherapy in prostate cancerPhilip Sutera, Matthew P Deek, Kim Van der Eecken, et al.
Cancer|June 29, 2019
Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national databaseAmandeep R Mahal, Santino Butler, Idalid Franco, et al.
Nature Communications|November 19, 2025
Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironmentSebastian Krossa, Maria K Andersen, Elise M Sandholm, et al.
JNCI Cancer Spectrum|April 24, 2026
Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trialPatrick Lewicki, Arnav Srivastava, Ralph Jiang, et al.
European Urology|March 14, 2024
Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN StudySoumyajit Roy, Fred Saad, Shawn Malone, et al.
European Urology Focus|July 30, 2017
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
European Urology Open Science|January 15, 2026
Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific OutcomesRyan M Putney, Purvish Trivedi, Shivanshu Awasthi, et al.
European Urology|December 14, 2020
A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)Luca F Valle, Eric J Lehrer, Daniela Markovic, et al.
Pageof 50